6VX Stock Overview
Engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Healios K.K. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥0.94 |
| 52 Week High | JP¥1.53 |
| 52 Week Low | JP¥0.66 |
| Beta | 0.92 |
| 1 Month Change | -18.70% |
| 3 Month Change | -31.75% |
| 1 Year Change | -14.22% |
| 3 Year Change | -90.62% |
| 5 Year Change | n/a |
| Change since IPO | -93.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6VX | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -7.4% | -0.8% | -1.6% |
| 1Y | -14.2% | -13.0% | 6.8% |
Return vs Industry: 6VX matched the German Biotechs industry which returned -13.2% over the past year.
Return vs Market: 6VX underperformed the German Market which returned 6.8% over the past year.
Price Volatility
| 6VX volatility | |
|---|---|
| 6VX Average Weekly Movement | 5.5% |
| Biotechs Industry Average Movement | 6.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6VX has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 6VX's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 64 | Hardy Kagimoto | www.healios.co.jp |
Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051 for treatment of ischemic stroke and acute respiratory distress syndrome; HLCN061 for treating solid tumors; HLCR011 for the treatment of retinal pigment epithelium tear and age-related macular degeneration; and HLCL041 for liver disease. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013.
Healios K.K. Fundamentals Summary
| 6VX fundamental statistics | |
|---|---|
| Market cap | €93.75m |
| Earnings (TTM) | -€38.07m |
| Revenue (TTM) | €3.36m |
27.9x
P/S Ratio-2.5x
P/E RatioIs 6VX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6VX income statement (TTM) | |
|---|---|
| Revenue | JP¥549.00m |
| Cost of Revenue | JP¥98.00m |
| Gross Profit | JP¥451.00m |
| Other Expenses | JP¥6.67b |
| Earnings | -JP¥6.22b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 14, 2025
| Earnings per share (EPS) | -69.03 |
| Gross Margin | 82.15% |
| Net Profit Margin | -1,133.33% |
| Debt/Equity Ratio | 117.8% |
How did 6VX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 14:28 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Healios K.K. is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hidemaru Yamaguchi | Citigroup Inc |
| Akinori Ueda | Goldman Sachs |
| Miyabi Yamakita | Jefferies LLC |